Arbaclofen | CAS#69308-37-8 | GABA-B agonist

MedKoo Cat#: 319756 | Name: Arbaclofen

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Arbaclofen, also known as (R)-Baclofen, D-Baclofen and STX209, is a selective GABA-B agonist and is hypothesized to modulate the balance of excitatory to inhibitory neurotransmission, and has shown preliminary evidence of benefit in fragile X syndrome. STX209 may be a potentially effective therapy to treat the core symptoms of FXS. Autism spectrum disorder (ASD) is a behaviorally defined disorder which has increased in prevalence over the last two decades.

Chemical Structure

Arbaclofen

CAS#69308-37-8 (free acid)

Theoretical Analysis

MedKoo Cat#: 319756

Name: Arbaclofen

CAS#: 69308-37-8 (free acid)

Chemical Formula: C10H12ClNO2

Exact Mass: 213.0557

Molecular Weight: 213.66

Elemental Analysis: C, 56.22; H, 5.66; Cl, 16.59; N, 6.56; O, 14.98

Price and Availability

Size	Price	Availability
500mg	USD 350.00	2 Weeks
1g	USD 550.00	2 Weeks
2g	USD 850.00	2 Weeks
5g	USD 1,650.00	2 Weeks
10g	USD 2,750.00	2 Weeks
25g	USD 4,250.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

69308-37-8 (free acid) 63701-55-3 (HCl)

Synonym

STX209; STX-209; STX 209; (R)-Baclofen; D-Baclofen; Arbaclofen

IUPAC/Chemical Name

(R)-4-Amino-3-(4-chlorophenyl)butanoic acid

InChi Key

KPYSYYIEGFHWSV-QMMMGPOBSA-N

InChi Code

InChI=1S/C10H12ClNO2/c11-9-3-1-7(2-4-9)8(6-12)5-10(13)14/h1-4,8H,5-6,12H2,(H,13,14)/t8-/m0/s1

SMILES Code

O=C(O)C[C@H](C1=CC=C(Cl)C=C1)CN

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO, not in water

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 213.66 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Okuda DT, Kantor D, Jaros M, deVries T, Hunter S. Arbaclofen extended-release tablets for spasticity in multiple sclerosis: randomized, controlled clinical trial. Brain Commun. 2022 Nov 23;4(6):fcac300. doi: 10.1093/braincomms/fcac300. PMID: 36519155; PMCID: PMC9732858. 2: Aishworiya R, Valica T, Hagerman R, Restrepo B. An Update on Psychopharmacological Treatment of Autism Spectrum Disorder. Neurotherapeutics. 2022 Jan;19(1):248-262. doi: 10.1007/s13311-022-01183-1. Epub 2022 Jan 14. PMID: 35029811; PMCID: PMC9130393. 3: Frye RE. Clinical potential, safety, and tolerability of arbaclofen in the treatment of autism spectrum disorder. Drug Healthc Patient Saf. 2014 May 10;6:69-76. doi: 10.2147/DHPS.S39595. PMID: 24872724; PMCID: PMC4025936. 4: Berry-Kravis E, Hagerman R, Visootsak J, Budimirovic D, Kaufmann WE, Cherubini M, Zarevics P, Walton-Bowen K, Wang P, Bear MF, Carpenter RL. Arbaclofen in fragile X syndrome: results of phase 3 trials. J Neurodev Disord. 2017 Jun 12;9:3. doi: 10.1186/s11689-016-9181-6. PMID: 28616094; PMCID: PMC5467054. 5: Okuda DT, Kantor D, Jaros M, deVries T, Hunter S. Arbaclofen extended-release tablets for spasticity in multiple sclerosis: open-label extension study. Brain Commun. 2023 Feb 7;5(1):fcad026. doi: 10.1093/braincomms/fcad026. PMID: 36861013; PMCID: PMC9968651. 6: Hopkins CR. ACS chemical neuroscience molecule spotlight on STX209 (arbaclofen). ACS Chem Neurosci. 2011 Aug 17;2(8):381. doi: 10.1021/cn200061g. Epub 2011 Jul 6. PMID: 22860166; PMCID: PMC3369760. 7: Veenstra-VanderWeele J, Cook EH, King BH, Zarevics P, Cherubini M, Walton- Bowen K, Bear MF, Wang PP, Carpenter RL. Arbaclofen in Children and Adolescents with Autism Spectrum Disorder: A Randomized, Controlled, Phase 2 Trial. Neuropsychopharmacology. 2017 Jun;42(7):1390-1398. doi: 10.1038/npp.2016.237. Epub 2016 Oct 17. PMID: 27748740; PMCID: PMC5436109. 8: Roberts TPL, Bloy L, Blaskey L, Kuschner E, Gaetz L, Anwar A, Ku M, Dipiero M, Bennett A, Edgar JC. A MEG Study of Acute Arbaclofen (STX-209) Administration. Front Integr Neurosci. 2019 Dec 4;13:69. doi: 10.3389/fnint.2019.00069. PMID: 31866839; PMCID: PMC6904329. 9: Lal R, Sukbuntherng J, Tai EH, Upadhyay S, Yao F, Warren MS, Luo W, Bu L, Nguyen S, Zamora J, Peng G, Dias T, Bao Y, Ludwikow M, Phan T, Scheuerman RA, Yan H, Gao M, Wu QQ, Annamalai T, Raillard SP, Koller K, Gallop MA, Cundy KC. Arbaclofen placarbil, a novel R-baclofen prodrug: improved absorption, distribution, metabolism, and elimination properties compared with R-baclofen. J Pharmacol Exp Ther. 2009 Sep;330(3):911-21. doi: 10.1124/jpet.108.149773. Epub 2009 Jun 5. PMID: 19502531. 10: Erickson CA, Veenstra-Vanderweele JM, Melmed RD, McCracken JT, Ginsberg LD, Sikich L, Scahill L, Cherubini M, Zarevics P, Walton-Bowen K, Carpenter RL, Bear MF, Wang PP, King BH. STX209 (arbaclofen) for autism spectrum disorders: an 8-week open-label study. J Autism Dev Disord. 2014 Apr;44(4):958-64. doi: 10.1007/s10803-013-1963-z. PMID: 24272415. 11: Vakil NB, Huff FJ, Cundy KC. Randomised clinical trial: arbaclofen placarbil in gastro-oesophageal reflux disease--insights into study design for transient lower sphincter relaxation inhibitors. Aliment Pharmacol Ther. 2013 Jul;38(2):107-17. doi: 10.1111/apt.12363. Epub 2013 May 30. PMID: 23721547. 12: Vakil NB, Huff FJ, Bian A, Jones DS, Stamler D. Arbaclofen placarbil in GERD: a randomized, double-blind, placebo-controlled study. Am J Gastroenterol. 2011 Aug;106(8):1427-38. doi: 10.1038/ajg.2011.121. Epub 2011 Apr 26. PMID: 21519360. 13: Gerson LB, Huff FJ, Hila A, Hirota WK, Reilley S, Agrawal A, Lal R, Luo W, Castell D. Arbaclofen placarbil decreases postprandial reflux in patients with gastroesophageal reflux disease. Am J Gastroenterol. 2010 Jun;105(6):1266-75. doi: 10.1038/ajg.2009.718. Epub 2009 Dec 29. PMID: 20040914. 14: Parellada M, San José Cáceres A, Palmer M, Delorme R, Jones EJH, Parr JR, Anagnostou E, Murphy DGM, Loth E, Wang PP, Charman T, Strydom A, Arango C. A Phase II Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of Arbaclofen Administered for the Treatment of Social Function in Children and Adolescents With Autism Spectrum Disorders: Study Protocol for AIMS-2-TRIALS-CT1. Front Psychiatry. 2021 Aug 24;12:701729. doi: 10.3389/fpsyt.2021.701729. PMID: 34504446; PMCID: PMC8421761. 15: Nance PW, Huff FJ, Martinez-Arizala A, Ayyoub Z, Chen D, Bian A, Stamler D. Efficacy and safety study of arbaclofen placarbil in patients with spasticity due to spinal cord injury. Spinal Cord. 2011 Sep;49(9):974-80. doi: 10.1038/sc.2011.43. Epub 2011 May 17. PMID: 21577221. 16: Berry-Kravis EM, Hessl D, Rathmell B, Zarevics P, Cherubini M, Walton-Bowen K, Mu Y, Nguyen DV, Gonzalez-Heydrich J, Wang PP, Carpenter RL, Bear MF, Hagerman RJ. Effects of STX209 (arbaclofen) on neurobehavioral function in children and adults with fragile X syndrome: a randomized, controlled, phase 2 trial. Sci Transl Med. 2012 Sep 19;4(152):152ra127. doi: 10.1126/scitranslmed.3004214. PMID: 22993294. 17: Scarpellini E, Ang D, Pauwels A, De Santis A, Vanuytsel T, Tack J. Management of refractory typical GERD symptoms. Nat Rev Gastroenterol Hepatol. 2016 May;13(5):281-94. doi: 10.1038/nrgastro.2016.50. Epub 2016 Apr 14. PMID: 27075264. 18: Borthwick L. Adulthood: Life lessons. Nature. 2012 Nov 1;491(7422):S10-1. doi: 10.1038/491s10a. PMID: 23136653. 19: Henderson C, Wijetunge L, Kinoshita MN, Shumway M, Hammond RS, Postma FR, Brynczka C, Rush R, Thomas A, Paylor R, Warren ST, Vanderklish PW, Kind PC, Carpenter RL, Bear MF, Healy AM. Reversal of disease-related pathologies in the fragile X mouse model by selective activation of GABAB receptors with arbaclofen. Sci Transl Med. 2012 Sep 19;4(152):152ra128. doi: 10.1126/scitranslmed.3004218. PMID: 22993295; PMCID: PMC8826584. 20: Kim GH. Arbaclofen placarbil decreases reflux with good tolerability in patients with gastroesophageal reflux disease (am j gastroenterol 2010;105:1266-1275). J Neurogastroenterol Motil. 2010 Oct;16(4):444-5. doi: 10.5056/jnm.2010.16.4.444. Epub 2010 Oct 30. PMID: 21103431; PMCID: PMC2978402.